Nektar Therapeutics
NKTR· Nasdaq
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $17.33M | $42.56M |
| Net Income | -$36.38M | -$517.00K |
| EPS Diluted | -$0.32 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nektar Therapeutics · CIK 906709 · Engraved from SEC EDGAR